Cue Biopharma Inc

NASDAQ:CUE  
0.78
-0.02 (-2.66%)
4:28:03 PM EDT: $0.80 +0.02 (+2.28%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)58.36M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.29 Million
Adjusted EPS-$0.09
See more estimates
10-Day MA$0.81
50-Day MA$0.79
200-Day MA$0.96
See more pivots

Cue Biopharma Inc Stock, NASDAQ:CUE

40 Guest Street, Boston, Massachusetts 02135
United States of America
Phone: +1.617.949.2680
Number of Employees: 53

Description

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.